Tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amide)
PreclinicalSmall molecule
Tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amide) is one of 6 small molecule programs targeting Analgesic. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in Analgesic
#DrugCompanyPhaseTrials
1Dynastat
PfizerPhase 3
Acupan
YYonsei University
Phase 2
Dexketoprofen Trometamol
MenariniPreclinical
Codeine Sulfate
HHikma Pharmaceuticals LLC
Preclinical
Tropisetron
UUniversity Hospital, Clermont-Ferrand
Preclinical
Tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amide)
PPrimorsky Regional General Hospital #1
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details